Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804
Q4 FY25 results · Jan–Mar 2025
Aurobindo Pharma reported revenue from operations of ₹8,382.12 crore (up 10.6% from Q4 FY24) and net profit of ₹902.83 crore (down 0.5% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8,382.12 | 7,580.15 | +10.6% | 7,978.52 | +5.1% |
| Other income | 134.81 | 135.62 | −0.6% | 157.29 | −14.3% |
| Total income | 8,516.93 | 7,715.77 | +10.4% | 8,135.81 | +4.7% |
| Profit before share of associates & JVs and tax | 1,367.28 | 1,242.56 | +10.0% | 1,198.26 | +14.1% |
| Share of profit/(loss) of associates & JVs | (32.19) | (12.66) | 1.59 | ||
| Net profit for the period | 902.83 | 907.35 | −0.5% | 845.57 | +6.8% |
| Attributable to shareholders of the company | 903.47 | 908.75 | −0.6% | 854.81 | +5.7% |
| EPS, basic (₹) | 15.56 | 15.51 | +0.3% | 14.56 | +6.9% |
| Net margin (%) | 10.8 | 12.0 | 10.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,731.99 | 2,894.03 | −5.6% | 2,916.63 | −6.3% |
| Other income | 113.98 | 122.97 | −7.3% | 54.26 | +110.1% |
| Total income | 2,845.97 | 3,017.00 | −5.7% | 2,970.89 | −4.2% |
| Profit before tax | 555.52 | 779.88 | −28.8% | 632.94 | −12.2% |
| Net profit for the period | 408.17 | 578.67 | −29.5% | 472.05 | −13.5% |
| EPS, basic (₹) | 7.03 | 9.88 | −28.8% | 8.13 | −13.5% |
| Net margin (%) | 14.9 | 20.0 | 16.2 |
Consolidated
- Filed with BSE
- 26 May 2025, 22:47 IST
- Board meeting
- 26 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 26 May 2025, 22:47 IST
- Board meeting
- 26 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE